Try our beta test site
152 studies found for:    Sjogren's Syndrome
Show Display Options
Download search resultsDownload the search results for:
Sjogren's Syndrome (152 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Low Dose Cyclosporin A in Primary Sjögren Syndrome
Condition: Sjögren´s Syndrome
Intervention: Drug: Cyclosporine A
2 Recruiting Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Drug: CFZ533 active - Cohort 1;   Drug: CFZ533 placebo- Cohort 1;   Drug: CFZ533 active - Cohort 2;   Drug: CFZ533 placebo - Cohort 2
3 Not yet recruiting Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
Condition: Primary Sjögren's Syndrome
Intervention: Other: Blood samples
4 Completed A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome
Conditions: Dry Mouth Associated With Sjogren's Syndrome;   Xerostomia
Interventions: Drug: Placebo;   Drug: 552-02
5 Completed Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome
Condition: Primary Sjogren's Syndrome
Intervention: Drug: Mycophenolate sodium
6 Recruiting Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Drug: CDZ173;   Drug: Placebo
7 Active, not recruiting PD of VAY736 in Patients With Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Drug: VAY736;   Drug: Placebo
8 Unknown  Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
Conditions: Sjogren's Syndrome;   Mesenchymal Stem Cells
Intervention: Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC)
9 Recruiting Study of Iguratimod in Sjögren's Syndrome
Condition: Sjogren's Syndrome
Intervention: Drug: Iguratimod
10 Recruiting A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
Condition: Sjogren's Syndrome
Interventions: Drug: Matching Placebo;   Drug: RO5459072
11 Recruiting A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Biological: AMG 557/MEDI5872;   Other: Placebo
12 Completed Neurotrophins Implications in Primary Sjögren Syndrome
Condition: Primary Sjögren Syndrome
Intervention: Biological: blood sample
13 Recruiting A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome
Condition: Primary Sjögren's Syndrome
Interventions: Drug: hrIL-2 active;   Drug: hrIL-2 placebo
14 Recruiting Implantology and Sjögren's Syndrome
Condition: Sjogren's Syndrome
Intervention: Device: Biohorizons Laser-lok bonelevel dental implants
15 Recruiting UCB Proof of Concept Study in Patients With Primary Sjogren's Syndrome
Condition: Primary Sjogren's Syndrome
Interventions: Drug: UCB5857;   Drug: Placebo
16 Completed Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: LimphoStat-B
17 Recruiting Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome
Condition: Sjögren's Syndrome
Interventions: Drug: SS-1;   Drug: Placebo
18 Recruiting Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome
Condition: Sjögren's Syndrome
Interventions: Drug: SS-1;   Drug: Placebo
19 Completed Etanercept Therapy for Sjogren's Syndrome
Condition: Sjogren's Syndrome
Intervention: Drug: Etanercept
20 Completed Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: Belimumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.